Heart Failure

A new analysis of data from the HOMAGE study addresses previous mixed results on the use of aspirin among patients who may be at risk of heart failure (HF).

Wanting more data on the benefits of sacubitril/valsartan vs renin angiotensin system inhibitor background therapy, investigators conducted a large randomized study among persons with heart failure with preserved ejection fraction (HFpEF).

Adriaan Voors, MD, professor of cardiology and director of the Heart Failure Clinic, University Medical Center Groningen, the Netherlands, addresses the lack of prescribing for sodium-glucose co-transporter 2 (SGLT2) inhibitors during hospitalization for acute heart failure by highlighting their benefits and that they are part of guideline-directed treatment.

Outcomes of in-hospital mortality, 7-day mortality, and emergency department length of stay were investigated among a cohort of patients with acute heart failure and hypercapnia, or excessive levels of CO2 in the blood.

Individuals with a history of acute myocardial infarction (AMI), or heart attack, may benefit on several fronts following early administration of the neprilysin inhibitor/angiotensin receptor blocker sacubitril/valsartan.

The counties in the United States with more social vulnerabilities had higher premature mortality related to cardiovascular diseases, such as heart disease, stroke, high blood pressure, and heart failure.

For 3 categories of evaluation, elevated cardiac troponin I levels most influenced the development of myocardial injury among persons at higher lifetime weight totals.

The task force determined that potential harms of adults aged 60 and older using aspirin for prevention outweighed the benefits.

The prevention document, released during ESC Congress 2021, marked the first update of this section of the guidelines in 8 years. It featured changes that reflect the arrival of a pair of drug classes with proven benefits in CV outcomes but that experts say are underutilized.

New research presented at the AHA Hypertension Scientific Sessions 2021 showed that men aged 20 to 49 years and women 70 and older both had a greater risk of hypertension.

In an interview for ESC Congress 2021, Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School, describes the treatment outlook for patients with heart failure with preserved ejection fraction (HFpEF).

On this episode of Managed Care Cast, we speak with Susan Quaggin, MD, FASN, a nephrologist and the chief of nephrology/hypertension and director of the Feinberg Cardiovascular and Renal Research Institute at Northwestern University, as well as current president of the American Society of Nephrology (ASN). She discusses the recommendations of the National Kidney Foundation (NKF) and ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Diseases and what comes next for laboratories, clinicians, and patients.

For patients with heart failure and cardiovascular disease, high intensity interval training has a greater positive effect on cardiorespiratory fitness than moderate intensity continuous training.

Long-awaited reports released Thursday call for eliminating race in estimated glomerular filtration rate equations and point to alternatives in an effort to eliminate disparities in chronic kidney disease.

With empagliflozin, we now have evidence that another treatment for patients with heart failure with preserved ejection fraction (HFpEF) is possible, said Stefan Anker, MD, PhD, FESC, professor of cardiology, Department of Cardiology, Charité Campus Virchow Clinic, Berlin, Germany, and principal investigator of the EMPEROR-Preserved study.

This study found that switching from a conventional troponin assay to a high-sensitivity troponin assay resulted in changes to diagnosis patterns and stress testing trends.

The 6-month program provides nutrition education, healthy food and recipes, and home visits.

Entresto (sacubitril/valsartan) was first approved for use in heart failure with reduced ejection fraction (HFrEF) in 2015.

In a panel at the 5th annual Heart in Diabetes Conference, John McMurray, MD, and Javed Butler, MD, highlighted recent pharmacological developments in heart failure (HF) and offered insights on overlooked areas in the field.

The Lancet commission aimed to connect stakeholders, raise global awareness of these inequities and disparities, and encourage future research.

Treatment for heart failure with preserved ejection fraction (HFpEF) may soon resemble that for heart failure with reduced ejection fraction (HFrEF), noted Javed Butler, MD, MPH, MBA, of the University of Mississippi.

Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been shown to both lower blood pressure and promote weight loss, and they act rather subtly, stated Rudolf de Boer, MD, PhD, clinical cardiologist and professor of translational cardiology, University Medical Center Groningen, the Netherlands.

STEP findings build on those from the SPRINT trial, seemingly confirming that intensive treatment for hypertension can reduce the risk of serious adverse cardiovascular (CV) outcomes. However, there was no significant benefit toward risk for all-cause and CV-related mortality.

Although there is an established link between type 2 myocardial infarction (T2MI) and elevated rates of cardiovascular events, less is known about the connection between T2MI and heart failure—which this new study investigated.

Because cardiac fibrosis can develop under very diverse etiological circumstances, it is extremely heterogeneous.